Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial

Inclusion Criteria: * Patient must be at least 18 years of age * Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the DESolve Myolimus Eluting BCSS and he/she or his/her legally authorized representative provides written informed consent, as approved by the appropriate Ethics Committee of the respective clinical site, prior to any clinical study related procedure * Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study electrocardiogram (ECG) changes consistent with ischemia) * Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery * Patient must agree to undergo all clinical study required follow-up visits, angiograms, IVUS, OCT and MSCT * Patient must agree not to participate in any other clinical study for a period of two years following the index procedure Exclusion Criteria: * Patients has a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure and CK and CK-MB have not returned within normal limits at the time of procedure * The patient is currently experiencing clinical symptoms consistent with AMI * Patient has current unstable arrhythmias Patient has undergone previous percutaneous interventions for lesions in either a non-target vessel or target vessel Patient has undergone previous percutaneous interventions for lesions in either a non-target vessel or target vessel * Patient has a known left ventricular ejection fraction (LVEF) \< 30% * Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant * Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure * Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) * Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g., heparin, coumadin) * Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine, Myolimus, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated * Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel * Patient has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3, a WBC of \< 3,000 cells/mm3, or documented or suspected liver disease. * Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, or patient on dialysis) * Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions * Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months * Patient has had a significant GI or urinary bleed within the past six months * Patient has extensive peripheral vascular disease that precludes safe 7 French sheath insertion * Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year) * Patient is already participating in another clinical study * Women of childbearing potential who have not undergone surgical sterilization or is not post-menopausal (defined as amenorrheic for at least one year)